Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px
Document › Details

MorphoMed GmbH. (9/7/17). "Press Release: MorphoMed – New Start-up Focusing on Next-generation Tissue Engineering in Vienna".

Organisation Organisation MorphoMed GmbH
Products Product MediSilk technology
  Product 2 RegACL regenerative medical silk ACL (anterior cruciate ligament)) transplant
     


MorphoMed aims to become a leading development company for tissue engineering of ligaments and tendons based on its proprietary medical silk (MediSilk) technology, thus leading to tissue regeneration and recovery of the body’s own functional tissue.


MorphoMed is a medtech start-up company founded in Vienna in May 2017 and focuses on the development of new regenerative implants based on its proprietary medical silk (MediSilk) technology. Silk can be completely cleaned from its antigenic sericin layer even in complex textile structures such as a braided ACL (anterior cruciate ligament).

Our first lead product RegACL, a regenerative medical silk ACL transplant might help hundreds of thousands of patients after an ACL rupture to get back to normal life and including sports activities only weeks after surgery and to fully regenerate their ligaments over the years.

“To morph” means “to transform in appearance, form or character”. In our case, MorphoMed’s novel MediSilk-based tissue engineering scaffolds are transformed into new body tissue. The lead product RegACL provides immediate stability for the patient and fully mimics the mechanical properties of the natural ACL. Furthermore, it undergoes slow biological degradation and simultaneously a new ligament is formed including aligned collagen fiber bundles, vascularization and anchoring bone tissue.

.In the future, the principle of tissue regeneration will become one of the most important sectors of modern medical device technology, since all implants, be they steel, polymers or other materials, have their limitations and will never fully mimic human tissue, especially not in the long term.

“It is a great opportunity to develop this exciting regenerative technology together with our partners, the Ludwig Bolzmann Society for experimental and clinical Traumatology under Prof. Heinz Redl and the FH Technikum Wien”, says Bernhard Küenburg, CEO of MorphoMed. “Especially the excellent proof of concept data in large animals (sheep) motivates us very much to develop this product and initialize a human clinical trial as fast as possible to get the CE and FDA certification.”


Contact:

MorphoMed GmbH
Dr. Bernhard Küenburg, CEO
office@morphomed.at
Löwengasse 45
1030 Vienna, Austria

   
Record changed: 2018-04-15

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px